N4 Pharma (LON:N4P) shares ticked up on Monday after the company announced a positive set of results from its Nuvec research study.
The pharmaceutical firm, which specialises in developing vaccines and cancer treatment, conducted research to determine the immune response that Nuvec can produce.
According to the statement, the research study revealed that Nuvec(R) particles have a ‘clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA OVA antigens comparable to that of existing delivery systems.’
Consequently, this would mean that Nuvec would not require the introduction of an additional adjuvant when formulating a vaccine using the delivery system.
N4 Pharma said this would simplify the process and reduce costs relating to the development of the vaccine.
In addition, the study revealed that the level of immune response from Nuvec remains within acceptable levels, demonstrating no adverse toxicity effects.
Nigel Theobald, CEO of N4 Pharma commented:
“These results are another positive step forward for our Nuvec(R) delivery platform. The data validates the potential of Nuvec(R) to act as an alternative delivery system for the development of vaccines and cancer treatments but without the associated unwanted systemic side effects and with no signs of liver toxicity often seen using lipid nanoparticle systems.
“Our next research study will focus on demonstrating the ability of Nuvec(R) to deliver an effective level of immunity using OVA, results of which will be available in first half of 2019.
“We are pleased with the Nuvec(R) results received to date and will continue to focus on the many opportunities that we believe will exist for Nuvec(R) to be used to develop a range of different vaccines and cancer treatments. We are building a compelling data package to aide our commercial collaboration discussions which we continue to progress.”
Shares in N4 Pharma are currently trading +18.37% as the market reacts to the research results.
Read more about our N4 Pharma stock analysis from February, here.